cyrilzakka/clinical-trials huggingface dataset:
An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia

This is a multicenter, ambispective observational cohort study. The patients with corona virus disease 2019 (COVID-19) will be included in the study. The patients will be divided into 4 groups according to the treatment mode (Azvudine treatment group within 48 hours after the first positive for nucleic acid, Azvudine treatment group after 48 hours after the first positive for nucleic acid, short course of Azvudine treatment without nucleic acid turning negative, and the control group) . This study aims to analyze the efficacy and safety of Azvudine in the treatment of patients with COVID-19.


Eligibility Criteria:
Inclusion Criteria:

* Patients with confirmed diagnosis of COVID-19 pneumonia
* Patients with the ability to take medication orally

Exclusion Criteria:

* Severe vomiting and difficulty in taking oral medication or ingestion of drugs after oral administration
* Suspected or confirmed active systemic infection other than COVID-19 pneumonia
* Pregnant or lactating women
* Patients with mental disorders
* Patients with severe liver damage
* Patients who are treated with small molecule drugs such as Nirmatrelvir Tablets/Ritonavir Tablets(co-packaged)
* Patients who are treated with RNA-dependent RNA polymerase (RDRP) inhibitors (Junshipharma VV116, Ascletis Pharma Inc. Asc10, Kexing biopharm Shen26, and Molnupiravir).
Oxygenation of the Cerebrum and Cooling During TAVI - Part I

Assessment of safety and feasibility of using a nasopharyngeal cooling technique to provide targeted brain cooling during percutaneous implantation of aortic valves. Was it possible to obtain brain temperatures below 34° within a reasonable time interval (max of 1hr) without delaying the procedure of valve implantation.

OCCTAVI-I Protocol

6 patients selected for Transcutaneous Aortic Valve Implantation (TAVI)-procedure will be subjected to intra-operative transnasal cooling (RhinoChill) ; cooling will be started after induction of anesthesia until tympanic temperature achieves 34° (cooling will be continued until 33°C of tympanic temperature, below 33°C active cooling will be stopped)

No intra-aortic catheter will be inserted before tympanic temperature reaches 34°

The aim of this study is to test the safety (as referring to routinely used neuromonitoring : ForeSight cerebral tissue oxygen saturation (SctO2) monitoring; and as referring to cardiovascular stability : blood pressure \& heartrate) and feasibility (as referring to temperature characteristics) of brain cooling during TAVI (cerebral (or tympanic) cooling rate, differential tympanic-rectal cooling rate, rectal cooling rate, time needed to obtain tympanic temperature below 34°)

Patients will be monitored with FORE-SIGHT cerebral oximeter (regional cerebral oxygen saturation, sensors placed on patient's forehead) and BIS VISTA (bilateral continuousEEG).

Tympanic temperature will be measured every 5 minutes while oesophageal and blood temperature will be continuously measured.

* Neuromonitoring (Fore-Sight, Bispectral Index (BIS) Vista) will be started before induction of anesthesia and cooling
* Transnasal cooling will be started after induction of anesthesia until a target tympanic temperature of 34°C
* Core temperature will not be monitored by esophageal (caveat interaction TEE probe), but by rectal and blood temperature
* TAVI-procedure will be started at a tympanic temperature of 34°C
* Arterial CO2 tension (PaCO2) will be checked every 30 minutes intra-operatively (target=normocapnia) by arterial blood gas analysis to maintain strict normocapnia
* and the end of the TAVI-procedure, patient will be rewarmed at a max rate of 0.8°/h by total body bair hugger
* when patient reaches tympanic and systemic (rectal) temperature of 35.5°C, extubation can be performed

Eligibility Criteria:
Inclusion Criteria:

* pts eligible for TAVI interventions

Exclusion Criteria:

* urgent intervention
A Study on Pain After Breast Reconstruction

The purpose of this study is to find out how common persistent postmastectomy pain (PPMP) is among people who have had a mastectomy and breast reconstruction surgery for their breast cancer. The study will also look at how effective regenerative peripheral nerve interface (RPNI) surgery is for reducing pain from neuropathic PPMP after breast reconstruction.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Age ≥18 years
* History of mastectomy for breast cancer or genetic predisposition to breast cancer
* History of breast reconstruction with implants and/or autologous tissue
* At least 6 months of follow-up after reconstruction
* Patient treated at MSK

Exclusion Criteria:

* Exchange or revision surgery within 6 months
* Active medical reason for pain (e.g., infectious, neoplastic, wound related)
* Greater than 15 years post-reconstruction
Regulation of Choroidal Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure

Autoregulation is the ability of a vascular bed to maintain blood flow despite changes in perfusion pressure. For a long time it had been assumed that the choroid is a strictly passive vascular bed, which shows no autoregulation. However, recently several groups have identified some autoregulatory capacity of the choroid. Choroidal autoregulation was first shown in a rabbit model where intraocular pressure (IOP) and arterial blood pressure could be varied independently. In these experiments regulation of choroidal blood flow was not only dependent on ocular perfusion pressure, but was also dependent on the value of IOP. This indicates that a myogenic mechanism contributes to choroidal autoregulation, because the regulatory capacity is dependent on the transmural pressure. In the model of myogenic autoregulation arterioles change their vascular tone depending on the pressure inside the vessel and outside the vessel. The present experiments are designed to test whether a myogenic mechanism may also be involved in choroidal autoregulation in humans. For this purpose the investigators perform experiments during which the IOP and the arterial blood pressure is increased. According to the myogenic theory of autoregulation one would expect stronger vasoconstriction at lower IOPs for the same increase in ocular perfusion pressure.


Eligibility Criteria:
Inclusion Criteria:

* Men aged between 19 and 35 years, nonsmokers
* Body mass index between 15th and 85th percentile
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
* Normal ophthalmic findings, ametropia \< 1 Dpt.

Exclusion Criteria:

* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
* Treatment in the previous 3 weeks with any drug
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Blood donation during the previous 3 weeks
* Presence of intraocular pathology: ocular hypertension, glaucoma, retinal vasculopathy or other retinal diseases
The Effectiveness of Transcutaneous Electrical Nerve Stimulation After Thoracic Surgery

The purpose of this randomised and controlled study is to investigate the effects of transcutaneous electrical nerve stimulation combined with physiotherapy and rehabilitation program on pulmonary function and functional exercise capacity.

Post-thoracotomy pain is one of the most severe types of post-surgical pain. When pain after thoracotomy is not treated effectively, it causes decrease in pulmonary compliance, inability to cough and deep breathing. Increased secretion leads to atelectasis and pneumonia. After surgery, early mobilization, providing airway cleaning (humidification, aspiration, forced expiration, assisted coughing), oxygen therapy, controlled breathing exercises, the use of incentive spirometry and such selected exercises, including posture and general exercises physiotherapy and rehabilitation approaches can prevent complications. A carefully planned pre and postoperative chest physiotherapy and rehabilitation program minimizes postoperative complications; it will restore normal function in these patients. Post-surgical physiotherapy applications should be combined with pain therapy for effective participation of the patient.

Local anesthetics, opioids and different special analgesia techniques including intercostal, paravertebral, interpleural and epidural blocks are used to relieve pain after thoracotomy. However, these techniques have serious side effects such as nausea, vomiting, respiratory depression, and sleepiness. It has been reported that the use of Transcutaneous Electrical Nerve Stimulation (TENS), in addition to traditional analgesia methods, may reduce the use of analgesics, side effects, and postoperative recovery period, and is useful for pain control. After cardiac surgery, TENS has been found useful in the treatment of postoperative incision pain. It has been reported that TENS therapy after thoracotomy as effective as patient-controlled analgesia.

Therefore, this study planned to investigate the effects of transcutaneous electrical nerve stimulation combined with physiotherapy and rehabilitation program on pulmonary function and functional exercise capacity in patients undergoing thoracic surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing lobectomy for lung cancer

Exclusion Criteria:

* Patients undergoing pneumonectomy.
* Patients undergoing smaller resection than lobectomy.
* Presence of serious arrhythmia, pacemaker, severe cardiac failure,
* Patients with cooperation disorder
* Presence of neurological or orthopedic problems affecting the extremities.
* Patients with severe psychiatric disorders
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.


Eligibility Criteria:
Inclusion Criteria (main criteria):

* Postmenopausal women (hysterectomized or not).
* Women between 40 and 80 years of age.
* Being in a stable relationship with the opportunity for sexual activity or masturbation at least once a month during the last 6 months or longer (before screening visit) and during the following 8 months.
* Diagnosis of HSDD confirmed by a qualified clinician.
* Willing to participate in the study and sign an informed consent.

Exclusion Criteria (main criteria):

* Chronic or acute life stress or major life change that could have interfered and continues to interfere significantly with sexual activity.
* Taking drugs which could be responsible for HSDD.
* Severe medical condition which can explain the loss of sexual desire.
* The administration of any investigational drug within 30 days of screening visit.
* Clinically significant abnormal serum biochemistry, urinalysis or hematology.
Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

This is a multi-center convenience sample prospective study comparing the results of the Verify Now® Aspirin Test and PRUTest® Platelet Reactivity Tests with the Japan investigational reagents to reagents registered in Japan in the expected population receiving aspirin (ASA) and the P2Y12 inhibitor clopidogrel.

* The Primary Objectives of this study are to compare the results of:
* The VerifyNow Aspirin Test with AA, an investigational reagent as defined in Japan, against LTA with AA investigational reagent as defined in Japan (study reference reagent), in subjects receiving DAPT (ASA and clopidogrel or subjects taking no platelet inhibitors including ASA;
* The VerifyNow Aspirin Test with AA, an investigational reagent as defined in Japan, against LTA with collagen (study reference reagent),

  o In subjects receiving DAPT (ASA and clopidogrel) or in subjects taking no platelet inhibitors including ASA
* The VerifyNow PRUTest with ADP, an investigational reagent as defined in Japan, and PGE1, against LTA with ADP, an approved reagent in Japan (study reference reagent) and PGE1, and
* The VerifyNow PRUTest with ADP (an investigational reagent as defined in Japan) and PGE1 against LTA with ADP reagent approved in Japan (study reference reagent) with no PGE1, o in up to 75 subjects receiving DAPT (ASA and clopidogrel) and in up to 55 subjects taking no platelet inhibitors (total up to 130 subjects).

Eligibility Criteria:
Inclusion Criteria:

* Males and females 18 years of age or older.
* Subjects regularly taking ASA and clopidogrel, for a minimum of 4 days prior to enrollment, or subjects taking no platelet inhibitors including ASA.
* Willing to participate and able to understand the study, including their rights and any risks associated with their participation, and sign an informed consent.
* Able and willing to donate a blood sample of 15mL.

  • Exclusion Criteria
* Enrolled in any other study that involves an investigational drug and/or device.
* Smoked within one hour before blood draw.
* Had caffeine within 2 hours before blood draw.
* Had meals with high fat content within 8 hours before blood draw.
* A platelet count below 92,000/µL, or above 502,000/µL for VerifyNow Aspirin Test.\*
* A platelet count below 119,000/µL, or above 502,00/µL for VerifyNow PRUTest.\*
* A hematocrit level below 29%, or above 56% for VerifyNow Aspirin Test.\*
* A hematocrit level below 33%, or above 52% for VerifyNow PRUTest.\*
* Within the past 48 hours, exposure to any of the following drugs:

  * Antiplatelet/glycoprotein inhibitors \[eptifibatide, tirofiban\]
  * Any antiplatelet drug except clopidogrel and ASA \[e.g. ticagrelor, prasugrel\]
Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Ankle Arthropathy

Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy.

Objective. To assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, stability, joint pain, joint status and the perception of quality of life in patients with hemophilic ankle arthropathy.

Study design. Randomized, multicenter, single-blind clinical study. Method. 32 patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 4 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (SF-36 scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and stability (The Single Leg Stance Test). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks.

Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, stabilit, and the perception of quality of life in patients with hemophilic ankle arthropathy.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with hemophilia A and B
* People with a medical diagnosis of hemophilic ankle arthropathy
* Patients over 18 years of age
* Paceinets in prophylactic or on-demand treatment regimen with FVIII/FIX concentrates.
* Failure to sign the informed consent document

Exclusion Criteria:

* Patients with neurological or cognitive alterations that prevent understanding of the questionnaires
* Amputee patients, epileptics or patients with severe vision problems
* Patients who are receiving physiotherapy treatment at the time of the study
Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma

This is a multi-center, prospective, randomized study which will enroll patients undergoing endoscopic surveillance due to a history of histologically confirmed dysplasia. A member of the research team will approach a potential subject to discuss participation in the study, including background of the proposed study, inclusion and exclusion criteria, benefits and risks of the procedures and follow-up. If this is of interest to the subject, the informed consent form is discussed and presented. The subject must sign the consent form prior to enrollment. This form will have prior approval of the study site's Institutional Review Board (IRB). Failure to obtain informed consent renders the subject ineligible for the study.


Eligibility Criteria:
Inclusion Criteria:

1. Patients age: ≥ 18 years
2. Patients should have a history of Barrett's associated esophageal dysplasia (either low or high-grade) confirmed on histology
3. Willingness to undergo both WATS3D and random forceps biopsies while undergoing conventional EGD with sedation
4. Ability to provide written, informed consent (approved by IRB) and understand the responsibilities of trial participation
5. Only patients who no visible mucosal abnormalities at the time that they undergo both random forceps biopsies and WATS3D testing of the esophagus will be included in this study

Exclusion Criteria:

1. Coagulopathy with INR \> 2.0, thrombocytopenia with platelet counts \< 50,000
2. The subject is pregnant or planning a pregnancy during the study period
3. History of esophageal or gastric surgery other than Endoscopic Mucosal Resection (EMR)
4. Patients who have undergone endoscopic ablative therapies
5. Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines
6. Study patients with inadequate WATS3D specimens will not undergo a repeat brush biopsy test and will be excluded from the study
7. BE length \< 1 cm or \> 10 cm
8. Patients within six weeks of receiving targeted forceps biopsies and/or EMR
9. Patients with visible mucosal abnormality at the time of the WATS3D and random biopsy testing
10. Patients with visible lesions that are either submucosal or covered with a clinically intact epithelium
The Effect of Video Training o Symptom Management With Heart Failure

The purpose of this clinical study is to compare the effect of video-assisted training on the quality of life and symptom management of patients over the age of 65. The main questions it aims to answer are:

-Is there a difference between symptom management and quality of life between the first and last follow-up periods of patients in the application and control groups?

Heart failure is the primary disease of old age. 20% of the reasons for hospital admission for patients aged 65 and over are due to heart failure.The most common symptoms in patients with heart failure are; fatigue, weakness, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema and changes in mental status.Due to these physical symptoms; there is a decrease in the functional capacity of patients, difficulty in performing daily life activities, inability to perform self-care, and the incidence of depression and anxiety increases.

In symptom management of patients with heart failure; these include knowing the clinical course of the disease, adapting to the disease and treatment, monitoring symptoms, educating the patient on self-care, and regular follow-up after discharge.It is stated that with patient education given to individuals in a planned and regular manner, the frequency and severity of the symptoms experienced decreases, the management and control of the disease is ensured, and thus the patient's quality of life is increased by creating the necessary behavioral changes.Due to the increase in the number of internet users in patient education, web-based education becomes more prominent.Thanks to video training, patients will be able to experience a permanent learning process by accessing the training content wherever they want, as often as they want.

Eligibility Criteria:
Inclusion Criteria:

* 65 years and above
* Volunteer to participate in the research
* Diagnosed with heart failure at least six months ago
* He/she/his relative has internet access and can use a smartphone
* Digital literacy scale score over 17
* Class I, II, III according to NYHA classification

Exclusion Criteria:

* Under 65 years of age
* Known serious vision and hearing problems
* With cognitive impairment
The Effect of Music on Surgical Skill in the Setting of Simulated Intraocular Surgery

Music is commonly heard in operating room. The goal of this study is to measure the effect of music on surgical performance using a intraocular surgery simulator. The music chosen is Sonata for 2 pianos D-440 from Mozart. The participants will complete 2 tasks on the simulator, both with and without music, in a randomized sequence. The results will be subtracted from the simulator and analyzed.


Eligibility Criteria:
Inclusion Criteria:

* Ophthalmology residents at Laval University
* Ophthalmologist at Centre Hospitalier Universitaire de Québec

Exclusion Criteria:

* None
New Non-invasive Methods for Real-time Monitoring of Organ Function.

Measuring novel proteins in the urine of surgical patients that can be used to diagnose impending acute or chronic renal failure.


Eligibility Criteria:
Inclusion Criteria:

* Patients \> 18 years of age

Exclusion Criteria:

* Patients at end stage renal disease
* Patients dependent on dialysis at time of surgery
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma

This research study is studying biomarkers in predicting response to chemotherapy in samples from young patients with osteosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study Population Description: Children's Oncology Group Sampling Method: Non-Probability Sample

PRIMARY OBJECTIVES:

I. Determine whether methylation status predicts response to neoadjuvant chemotherapy in samples from children and young adults with osteosarcoma.

OUTLINE: Patients are stratified according to response to neoadjuvant chemotherapy (good vs poor).

DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with high-grade osteoblastic osteosarcoma
* Biopsy samples from patients who had good or poor response to neoadjuvant chemotherapy available
* All specimens should be from post-menarchal females or age-matched males with appendicular tumors
* Patients' clinical data including chemotherapy received, event-free survival, and overall survival available
* See Disease Characteristics